Chan Thomas S Y, Luk Tsan-Hei, Lau June S M, Khong Pek-Lan, Kwong Yok-Lam
Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China.
Ann Hematol. 2017 Apr;96(4):647-651. doi: 10.1007/s00277-017-2931-z. Epub 2017 Jan 31.
Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100-200 mg, every 3 weeks). Complete response (CR) was achieved in four patients (80%), after a median cumulative dose of merely 495 (300-800) milligrams. Three CR patients have continued to receive pembrolizumab for a median of 16 (14-25) cycles, remaining in CR for a median of 18 (9-18) months. One CR patient underwent autologous hematopoietic stem cell transplantation and has remained in CR for 9 months. Partial response (PR) was achieved in one patient (20%), after a cumulative dose of 400 mg. The overall response rate was therefore 100% (CR: 80%; PR: 20%). Toxicity was virtually absent, with only grade 1 diarrhea and eczema each observed in one patient. Low-dose pembrolizumab was highly efficacious, achieving responses with minimal toxicity and at much lower costs.
五例难治性/复发性经典型霍奇金淋巴瘤（cHL）患者，其中四例对多线化疗及 Brentuximab vedotin 治疗均无效，接受了低剂量派姆单抗治疗（中位剂量 100mg，范围：100 - 200mg，每 3 周一次）。四例患者（80%）达到完全缓解（CR），中位累积剂量仅为 495（300 - 800）毫克。三例 CR 患者继续接受派姆单抗治疗，中位疗程为 16（14 - 25）个周期，持续处于 CR 状态的中位时间为 18（9 - 18）个月。一例 CR 患者接受了自体造血干细胞移植，目前已持续 CR 状态 9 个月。一例患者（20%）达到部分缓解（PR），累积剂量为 400mg。因此，总体缓解率为 100%（CR：80%；PR：）。几乎没有毒性反应，仅各有一例患者出现 1 级腹泻和湿疹。低剂量派姆单抗疗效显著，以最小的毒性和更低的成本实现了缓解。
